Literature DB >> 2893167

Thalidomide for graft-versus-host disease after bone marrow transplantation.

J H Saurat, M Camenzind, C Helg, B Chapuis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2893167     DOI： 10.1016/s0140-6736(88)91151-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

Review 2.  An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.

Authors:  W J Gradishar
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

3.  Thalidomide-induced neuropathy and genetic differences in drug metabolism.

Authors:  C C Harland; G B Steventon; J R Marsden
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 4.  Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations.

Authors:  V Günzler
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

5.  Thalidomide is an inhibitor of angiogenesis.

Authors:  R J D'Amato; M S Loughnan; E Flynn; J Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

Review 6.  The potential use of thalidomide in the therapy of graft-versus-host disease--a review of clinical and laboratory information.

Authors:  P M Wood; S J Proctor
Journal:  Leuk Res       Date:  1990       Impact factor: 3.156
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.